New drug approved for soft-tissue cancer

(HealthDay)—The chemotherapy drug Yondelis (trabectedin) has been approved by the U.S. Food and Drug Administration to treat certain soft-tissue sarcomas (STS) that have spread or can't be treated by surgery.

STS can form anywhere, but most often affects in the head, neck, arms, legs, trunk and abdomen, the agency said Friday in a news release. Some 12,000 cases were diagnosed in the United States last year.

Yondelis is approved for people with two forms of STS—liposarcoma or leiomyosarcoma—who have had previous treatment with chemotherapy that contained the drug anthracycline, the FDA said.

Yondelis was evaluated in clinical studies involving 518 people. People who took Yondelis had cancer progression stopped for an average of 4.2 months, compared to an average of 1.5 months among those who took another , the agency said.

The most common side effects of Yondelis include nausea, fatigue, vomiting, diarrhea, constipation, loss of appetite, shortness of breath, headache and tissue swelling.

The drug's label warns of the possibility of more serious side effects, including life-threatening blood infections, muscle breakdown, liver damage, leakage near the injection site and heart failure. It also warns women of childbearing age of potential harm to a developing fetus, and against breastfeeding while on the drug.

Yondelis is marketed by Janssen Products, based in Raritan, N.J.

Explore further

FDA approves new pancreatic cancer drug

More information: The U.S. National Cancer Institute has more about soft-tissue sarcoma.

Copyright © 2015 HealthDay. All rights reserved.

Citation: New drug approved for soft-tissue cancer (2015, October 23) retrieved 26 January 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments